After decades of neglect by the pharmaceutical industry, male infertility is finally getting serious clinical attention. At least three novel drugs are now in active clinical trials, each attacking the problem from a different biological angle. IGX12, a first-in-class monoclonal antibody developed by Igyxos Biotherapeutics, completed Phase 1 trials in December 2025 with positive safety results and is heading into Phase 2 trials at European fertility centers in 2026. Meanwhile, ReproNovo’s oral aromatase inhibitor RPN-001 enrolled its first U.S. participant in a Phase 2 trial in July 2025, and Danish company XY Therapeutics is running a Phase 2A trial of a single-injection RANKL inhibitor.
For the millions of men worldwide living with infertility, these represent the most promising pharmaceutical developments in a generation. The scale of the problem makes this progress long overdue. Approximately 55 million men between ages 15 and 49 were diagnosed with infertility as of 2021, a staggering 74.66 percent increase since 1990, according to research published in Frontiers in Endocrinology. Male factors contribute to nearly half of all infertility cases, serving as the sole cause in roughly 20 percent and a contributing factor in another 30 to 40 percent. Yet until now, there have been very few approved pharmaceutical treatments specifically designed for male infertility, leaving couples to rely heavily on assisted reproductive technologies that are expensive, invasive, and often focused on the female partner. This article examines each of the drugs now in trials, what they do, and what men dealing with infertility should realistically expect.
Table of Contents
- What New Drugs for Male Infertility Are Now in Clinical Trials?
- How IGX12 Works and Why It Represents a New Approach to Treating Low Sperm Count
- RPN-001 and the Case for an Oral Treatment Option
- Single-Injection Treatment from XY Therapeutics and How It Compares
- Why Male Infertility Has Been Underserved by Drug Development
- New Research That Could Shape Future Male Fertility Treatments
- What the Next Few Years Could Look Like for Male Infertility Treatment
- Conclusion
- Frequently Asked Questions
What New Drugs for Male Infertility Are Now in Clinical Trials?
Three distinct drug candidates stand out. The first, IGX12 from Igyxos Biotherapeutics, is a humanized monoclonal antibody that enhances the potency of follicle-stimulating hormone, or FSH, a key driver of sperm production. Rather than replacing FSH or injecting synthetic hormones, IGX12 amplifies what the body already produces. Phase 1 results released in December 2025 showed the drug was safe and well tolerated at both tested dose levels of 20 and 40 micrograms per kilogram, with no serious adverse effects. Its pharmacokinetic profile supports monthly dosing, which is a meaningful convenience advantage over treatments requiring daily administration. For men with oligozoospermia, or low sperm count, IGX12 could enhance sperm concentration with just a limited number of injections over the roughly 74-day spermatogenesis cycle. The second is RPN-001, also known as leflutrozole, an oral small-molecule aromatase inhibitor developed by ReproNovo. This drug blocks the conversion of testosterone into estradiol, thereby helping to normalize testosterone levels in men with low serum testosterone and impaired sperm quality.
Its Phase 2 trial is a randomized, placebo-controlled study enrolling approximately 200 men across multiple U.S. sites, evaluating three dose levels. This is significant because while aromatase inhibitors like letrozole and anastrozole have been used off-label for male infertility for years, RPN-001 is the first aromatase inhibitor specifically designed and tested for this indication. Expected completion is November 2026. The third candidate comes from XY Therapeutics, a Danish company targeting the RANKL/RANK/OPG pathway. Their treatment, delivered as a single injection, is based on research using denosumab, a RANKL inhibitor more commonly associated with osteoporosis treatment. A randomized clinical trial showed increased sperm concentration in a subgroup of infertile men with serum anti-Müllerian hormone levels at or above 38 picomoles per liter. The company currently holds two patents on the use of RANKL inhibitors for male infertility and is in Phase 2A trials.
How IGX12 Works and Why It Represents a New Approach to Treating Low Sperm Count
IGX12’s mechanism is unusual in the fertility drug landscape. Most hormonal treatments for male infertility involve either injecting synthetic FSH or using drugs like clomiphene citrate to indirectly boost the body’s hormone production. IGX12 takes a different route entirely. By binding to and enhancing the activity of naturally circulating FSH, the antibody essentially makes the existing hormone work harder. Think of it less as adding fuel and more as tuning the engine. The Phase 2 trials planned for 2026 at leading European fertility centers will be funded by a 5.7 million euro grant from the French government, awarded in October 2025, which signals both governmental confidence in the approach and the broader recognition that male infertility deserves dedicated research investment. However, there are important caveats.
IGX12 is designed specifically for men with oligozoospermia, meaning it targets low sperm count rather than other causes of male infertility such as poor motility, abnormal morphology, or obstructive conditions. Men whose infertility stems from genetic factors like Y-chromosome microdeletions or from physical blockages would not be candidates for this treatment. Additionally, because the drug enhances FSH activity, its effectiveness likely depends on the patient having functional Sertoli cells in the testes that can respond to FSH signaling. If those cells are severely damaged or absent, amplifying the hormonal signal may not produce meaningful results. The Phase 2 trials should clarify which patient subgroups benefit most. It is also worth noting that while the Phase 1 results are encouraging from a safety standpoint, they were designed to test tolerability rather than efficacy. Whether IGX12 actually improves sperm counts enough to result in pregnancies remains an open question that the Phase 2 data will need to answer.
RPN-001 and the Case for an Oral Treatment Option
For many men, the appeal of RPN-001 is straightforward: it is a pill. In a treatment landscape where many fertility interventions require injections, monitoring, and clinic visits, an oral medication that a man can take at home represents a meaningful reduction in burden. The drug works by inhibiting the aromatase enzyme, which converts testosterone to estradiol. In men with elevated estradiol levels relative to testosterone, this hormonal imbalance can suppress sperm production. By blocking that conversion, RPN-001 aims to restore a healthier testosterone-to-estradiol ratio and, in turn, improve spermatogenesis. Doctors have prescribed generic aromatase inhibitors off-label for this purpose for years, but that practice has always existed in a gray area.
Off-label use means no large, rigorous trials have established optimal dosing for male infertility, and insurance coverage is inconsistent. The fact that ReproNovo is running a proper Phase 2 randomized controlled trial with approximately 200 participants and three dose levels means that, for the first time, there will be high-quality evidence on whether this class of drug actually works for male infertility and at what dose. As reported by Urology Times, this makes RPN-001 the first-in-class aromatase inhibitor specifically designed and tested for this condition. One limitation worth flagging: aromatase inhibition is only relevant for men whose infertility involves a hormonal imbalance. Men with normal testosterone and estradiol levels, or those whose low sperm counts are driven by varicoceles, infections, or genetic factors, are unlikely to benefit. The Phase 2 trial’s inclusion criteria should help define the right patient population, but men interested in this approach should have their hormone panels checked before assuming it applies to them.
Single-Injection Treatment from XY Therapeutics and How It Compares
The XY Therapeutics approach is perhaps the most surprising of the three. The RANKL/RANK/OPG pathway is best known for its role in bone metabolism, which is why denosumab is primarily marketed as an osteoporosis drug. But emerging research has revealed this pathway also plays a role in testicular function and sperm production. The prospect of a single injection that could improve fertility outcomes is compelling, particularly when compared to the multi-month treatment regimens typically required for hormonal therapies. Where IGX12 envisions monthly dosing over a spermatogenesis cycle and RPN-001 requires daily oral medication, a one-time injection would be the least burdensome option by far. The tradeoff is specificity. The clinical data so far suggests that the treatment works in a defined subgroup: infertile men with serum AMH levels at or above 38 picomoles per liter.
AMH, or anti-Müllerian hormone, is not routinely measured in male fertility workups, which means this treatment would require additional diagnostic testing to identify eligible patients. Moreover, Phase 2A is still an early stage of development, and the jump from showing improved sperm concentration in a subgroup to demonstrating meaningful improvements in pregnancy rates across a broader population is significant. Couples weighing this option against alternatives should understand that the convenience of a single injection comes with uncertainty about how widely applicable the treatment will be. Comparing the three candidates side by side reveals different philosophies. IGX12 amplifies the body’s existing hormonal machinery. RPN-001 corrects a specific hormonal imbalance. XY Therapeutics’ approach modulates a pathway not traditionally associated with reproduction. Each targets a different subset of infertile men, which means they are not truly competitors but rather potentially complementary treatments for a condition with many underlying causes.
Why Male Infertility Has Been Underserved by Drug Development
The fact that these are among the first drugs specifically developed for male infertility raises an uncomfortable question: why did it take so long? Part of the answer is cultural. Infertility has historically been framed as a women’s health issue, with diagnostic workups and treatment plans centered on the female partner. Part of the answer is economic. Assisted reproductive technologies like IVF and ICSI, while expensive, are profitable and effective enough that pharmaceutical companies had little financial incentive to develop male-specific drugs when the industry could route around the problem by focusing on egg retrieval and embryo transfer. But the numbers tell a different story about need. The global age-standardized prevalence rate of male infertility is projected to rise more rapidly than female infertility from 2022 to 2040, according to research published in PubMed.
As noted by Drug Discovery World in March 2026, there are currently very few approved pharmaceutical treatments specifically for male infertility, and most existing options target narrow subgroups. This gap between prevalence and available treatments has left millions of men with limited options beyond lifestyle modifications, surgical correction of varicoceles, or hormonal therapies used off-label without robust evidence. The risk now is that expectations outpace reality. Phase 2 trials are designed to test whether a drug works, not to prove it ready for market. Many drugs that show promise in Phase 2 fail in Phase 3, where larger and more diverse patient populations can reveal problems not seen in smaller studies. Men and couples following these developments should maintain cautious optimism rather than treating clinical trial enrollment as a guarantee of an imminent cure.
New Research That Could Shape Future Male Fertility Treatments
Beyond the drugs currently in trials, basic science is opening new doors. In February 2026, researchers at Michigan State University identified a molecular switch that boosts sperm energy just before fertilization. This discovery has dual potential: it could improve infertility treatments by helping sperm function more effectively, and it could inform the development of nonhormonal male contraception by finding ways to block that energy surge.
While this research is still at the laboratory stage and years away from clinical application, it illustrates that the scientific community is finally investing seriously in understanding male reproductive biology at a molecular level. This kind of foundational research matters because it expands the target landscape. The current crop of clinical candidates focuses on hormonal pathways, but male infertility has many nonhormonal causes, including oxidative stress, DNA fragmentation, and cellular energy deficits. A richer understanding of sperm biology at the molecular level could eventually yield treatments for men whose infertility does not respond to hormone-based approaches.
What the Next Few Years Could Look Like for Male Infertility Treatment
If even one of the three drugs currently in trials succeeds, it will fundamentally change how reproductive medicine approaches male factor infertility. Instead of defaulting to IVF or ICSI as workarounds, clinicians could offer targeted pharmaceutical treatment that addresses the male partner’s underlying biology directly. The ReproNovo Phase 2 trial is expected to complete by November 2026, and IGX12’s Phase 2 trials in Europe are set to begin that same year.
Results from these studies will determine whether the field moves forward into larger Phase 3 trials or whether further refinement is needed. For men currently struggling with infertility, these developments are meaningful but not yet actionable outside of clinical trial participation. The practical advice remains the same for now: get a thorough diagnostic workup that includes hormone panels and semen analysis, discuss existing evidence-based options with a reproductive urologist, and consider enrolling in a clinical trial if eligible. The landscape is shifting in a way it never has before, and the next two to three years should reveal whether these promising early results translate into treatments that actually reach patients.
Conclusion
Male infertility affects roughly 55 million men worldwide, yet the pharmaceutical industry has historically offered almost nothing specifically designed to treat it. That is changing. IGX12, RPN-001, and XY Therapeutics’ RANKL inhibitor each represent a distinct and scientifically grounded approach to a problem that has been neglected for too long. The Phase 1 and Phase 2 data emerging from these trials mark the first time that purpose-built male infertility drugs are progressing through rigorous clinical evaluation, and each one targets a different subset of the condition’s many causes.
None of these drugs are available yet, and the road from clinical trials to pharmacy shelves is long and uncertain. But for the first time, men with infertility can look at a pipeline of treatments being developed with them specifically in mind. Those who want to stay informed should follow trial updates through ClinicalTrials.gov, discuss emerging options with their reproductive specialists, and consider whether trial participation might be appropriate for their situation. The science is finally catching up to the need.
Frequently Asked Questions
Are any of these new male infertility drugs available to patients now?
No. All three candidates, IGX12, RPN-001, and XY Therapeutics’ RANKL inhibitor, are currently in Phase 1 or Phase 2 clinical trials. They are not yet available by prescription. Some men may be eligible to participate in the ongoing trials, which can be found through ClinicalTrials.gov or by asking a reproductive urologist.
How is IGX12 different from existing FSH injections used in fertility treatment?
Traditional FSH injections add synthetic hormone to the body. IGX12 is a monoclonal antibody that enhances the potency of the FSH your body already produces, making existing hormone levels more effective rather than supplementing them externally. Its pharmacokinetic profile supports monthly dosing rather than more frequent injections.
Can these drugs help all men with infertility?
No. Each drug targets a specific underlying cause. IGX12 is designed for men with oligozoospermia, or low sperm count. RPN-001 addresses hormonal imbalances involving elevated estradiol relative to testosterone. XY Therapeutics’ treatment appears most effective in men with serum AMH levels at or above 38 picomoles per liter. Men with genetic causes, obstructive conditions, or other non-hormonal factors may not benefit from these particular drugs.
Why are aromatase inhibitors not already approved for male infertility if doctors prescribe them off-label?
Off-label use means a drug is prescribed for a condition it was not specifically approved to treat. While some doctors have used generic aromatase inhibitors like letrozole for male infertility, no company had conducted the rigorous, randomized clinical trials needed for regulatory approval in this indication until ReproNovo began its Phase 2 study of RPN-001 in July 2025.
When might these treatments become available if trials succeed?
Drug development timelines are uncertain, but if Phase 2 trials produce positive results, Phase 3 trials would likely follow, adding several more years before potential regulatory approval. Optimistically, the earliest any of these drugs could reach the market would be the late 2020s, assuming no significant setbacks.
Is male infertility becoming more common?
The data suggests yes. Approximately 55 million men worldwide were diagnosed with infertility as of 2021, representing a 74.66 percent increase since 1990. Research published in PubMed projects that the global age-standardized prevalence rate of male infertility will rise more rapidly than female infertility from 2022 to 2040.
